Quick Comparison

Methylene BluePEA (Palmitoylethanolamide)
Half-Life5-6 hours1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability
Typical DosageNootropic dose: 0.5-2 mg/kg body weight (typically 30-60 mg for most adults). Pharmaceutical grade USP only — never use industrial or aquarium-grade. Start at the lowest dose. Turns urine blue/green (harmless).Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks.
AdministrationOral (solution, capsules). Must be pharmaceutical/USP grade. Sublingual for faster absorption.Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability.
Research Papers10 papers10 papers
Categories

Mechanism of Action

Methylene Blue

Methylene blue has a unique property: it acts as an alternative electron carrier in the mitochondrial electron transport chain, cycling between oxidized (blue) and reduced (leuco) forms. It can accept electrons from Complex I (NADH) and donate them directly to cytochrome c, bypassing dysfunctional Complex II and III—maintaining ATP production when mitochondria are damaged or in hypoxic conditions. Methylene blue inhibits nitric oxide synthase (NOS), reducing NO production and the formation of peroxynitrite (ONOO-), a potent oxidant that damages mitochondria. It acts as a redox cycler with antioxidant properties and may enhance cytochrome c oxidase (Complex IV) activity. At low doses, it inhibits tau protein aggregation and tau-tau interactions (relevant to Alzheimer's pathology) and may improve mitochondrial respiration through multiple mechanisms.

PEA (Palmitoylethanolamide)

PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.

Risks & Safety

Methylene Blue

Common

Blue/green discoloration of urine and potentially skin at higher doses, nausea, headache.

Serious

Serotonin syndrome risk when combined with SSRIs, SNRIs, or MAOIs — DO NOT combine. Contraindicated in G6PD deficiency (can cause hemolytic anemia).

Rare

Confusion, shortness of breath, chest pain.

PEA (Palmitoylethanolamide)

Common

Very well-tolerated — rare side effects. Mild GI discomfort.

Serious

None documented. Over 30 clinical trials confirm excellent safety profile.

Rare

Skin rash.

Full Profiles